Last reviewed · How we verify
AADvac1 160 µg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
AADvac1 160 µg (AADvac1 160 µg) — Axon Neuroscience SE.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AADvac1 160 µg TARGET | AADvac1 160 µg | Axon Neuroscience SE | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AADvac1 160 µg CI watch — RSS
- AADvac1 160 µg CI watch — Atom
- AADvac1 160 µg CI watch — JSON
- AADvac1 160 µg alone — RSS
Cite this brief
Drug Landscape (2026). AADvac1 160 µg — Competitive Intelligence Brief. https://druglandscape.com/ci/aadvac1-160-g. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab